Sequence variants in the human 25-hydroxyvitamin D3 1-α-hydroxylase (CYP27BI) gene are not associated with prostate cancer risk

Gregory A. Hawkins, Scott D. Cramer, Siqun L. Zheng, Sarah D. Isaacs, Kathy E. Wiley, Bao Li Chang, Eugene R. Bleecker, Patrick C. Walsh, Deborah A. Meyers, William B. Isaacs, Jianfeng Xu

Research output: Contribution to journalArticlepeer-review


BACKGROUND. 1,25-dihydroxyvitamin D3 has been shown to have antiproliferative properties on normal and neoplastic prostatic cells. 25-hydroxyvitamin D3 1-α-hydroxylase, the enzyme that catalyzes the final step of vitamin D synthesis, converting 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3, is expressed in the prostate. METHODS. The human 25-hydroxyvitamin D3 1-α-hydroxylase gene (CYP27B1) was resequenced in a case/control panel consisting of 64 individuals (48 Caucasians and 16 African Americans), with equal numbers of hereditary prostate cancer cases, sporadic cases, and unaffected controls. Three frequent single nucleotide polymorphisms (SNPs) were genotyped in 245 prostate cancer cases and 222 controls. RESULTS. Six noncoding SNPs were identified in the CYP27B1 gene. No significant difference was found in allele and genotype frequencies between sporadic cases and unaffected controls for the three genotyped SNPs. CONCLUSION. This study suggests that the CYP27B1 gene does not play a major role as a prostate cancer susceptibility gene. Prostate 53: 175-178, 2002.

Original languageEnglish (US)
Pages (from-to)175-178
Number of pages4
Issue number3
StatePublished - Nov 1 2002


  • CYP27B1 polymorphisms
  • Prostate cancer
  • Vitamin D

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Sequence variants in the human 25-hydroxyvitamin D<sub>3</sub> 1-α-hydroxylase (CYP27BI) gene are not associated with prostate cancer risk'. Together they form a unique fingerprint.

Cite this